Abstract
We sought to evaluate the feasibility and hemodynamic performance of a new self-expanding bioprosthesis and 16-F delivery system in sheep. A 23-mm new self-expanding aortic bioprosthesis was implanted in sheep (n = 10) with a 16-F catheter via the right common carotid artery. Each sheep underwent angiography and coronary angiography before intervention, immediately and 1 h after stent implantation. Electrocardiographic monitoring was carried out during and 2 h after the procedure. Transthoracic echocardiography was employed to detect he-modynamic performance before intervention, immediately and 1 and 2 h after stent implantation. All sheep were euthanized 2 h after successful implantation for macroscopic inspection. In all cases, the new self-expanding aortic bioprosthesis was successfully delivered to the aortic root and released with a 16-F catheter. Successful implantation was achieved in 8 of 10 sheep. Hemodynamic performance and device position of successful implantation were stable 2 h after device deployment. Atrioventricular block was not observed. We conclude that it is feasible to implant the new self-expanding aortic valve with a 16-F delivery system into sheep hearts via the retrograde route.
Highlights
With increasing life expectancy and an aging population, the number of patients with aortic valve stenosis (AS) will increase
To improve the procedure and to reduce the prevalence of complications, we developed a new self-expanding revalving system (Venus A-valve, Hangzhou, China) with a relatively smaller lower one-third portion and a 16-F delivery system, which may cause less injury to the arteries and conductive bundles after implantation
Angiography revealed the mean diameter of the aortic annulus to be 19.56±1.61 mm
Summary
With increasing life expectancy and an aging population, the number of patients with aortic valve stenosis (AS) will increase. The prevalence of AS is 4.6% in adults aged ≥ 75 years[1]. A significant proportion of patients with symptomatic severe AS are denied or not offered surgery due to high surgical risk or non-operability for chest-opening replacement of the aortic valve[2,3,4,5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
